Industry Research Reports

Home > Reports > Service & Software > Lung Cancer Screening Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Lung Cancer Screening Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032

Industry: Service & Software

Published Date: 2026-01-14

Pages: 117 Pages

Report ld: 5649943

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Lung Cancer Screening Software Market Size(US$)

CAGR 2026-2032

18.0%

Market Size,2032

USD 5,434

Million

Market Snapshot

Market Size in 2026 (Value)

US$ 2,013 million

Market Forecast in 2032(Value)

US$ 5,434 million

CAGR

18.0%

Years Considered

2021-2032

Base Year

2026

Forecast Period

2026-2032

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Lung Cancer Screening Software was estimated to be worth US$ 1706 million in 2025 and is projected to reach US$ 5434 million, growing at a CAGR of 18.0% from 2026 to 2032.

Lung cancer screening software is medical software based on medical imaging (primarily low-dose CT) and algorithm models. It is used to automatically detect lung nodules, analyze morphological characteristics, assess malignancy risk, and assist in follow-up management. Its goal is to improve the early detection rate of lung cancer, reduce the missed diagnosis rate, and support clinical decision-making and population screening.

Upstream components mainly include medical imaging data sources (CT equipment, imaging centers), computing power and cloud infrastructure, algorithm frameworks, and data annotation resources. Downstream components primarily target hospital radiology departments, regional public health screening projects, physical examination institutions, and health management and insurance-related service scenarios.

Global Market Future Development Trends

With the increasing incidence of lung cancer and the aging population, low-dose CT screening is being included in recommended or pilot programs in more and more countries. Traditional manual image interpretation is insufficient to support large-scale screening, making efficient and replicable software solutions a necessity and driving the rapid deployment of lung cancer screening software in hospitals and regional population screening.

The market is evolving from single nodule detection to risk stratification, follow-up comparison, multi-temporal analysis, and automated reporting. Algorithm stability, cross-device generalization ability, and clinical interpretability have become core competitive advantages, elevating the value of software from an "auxiliary tool" to a "key node in the screening process."

Against increasingly stringent regulatory requirements from the FDA, CE, and NMPA, compliance certification has become a market entry barrier. In the future, software will increasingly take the form of platforms, integrating with PACS, regional screening systems, and cloud services, transforming from single-point sales to long-term service revenue through subscription or pay-per-view models.

This report provides a comprehensive view of the global market for Lung Cancer Screening Software, covering total sales revenue, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.

The Lung Cancer Screening Software market size, estimations, and forecasts are presented in terms of sales revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Lung Cancer Screening Software.

MARKET SEGMENTATION

By Company

Siemens Healthineers
GE HealthCare
Philips Healthcare
Canon Medical Systems
United Imaging Healthcare
InferVision
Airdoc
VUNO
Lunit
Qure.ai
Riverain Technologies
Zebra Medical Vision
Arterys
Deepwise
EverFortune AI

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Cloud-Based
Web-Based

Segment by Application

Hospitals
Medical Examination Institutions
Public Health Screening
Others

Segment by Category

Nodule Detection
Nodule Analysis
Full-Process Screening
Predictive Assessment

Segment by Division

Standalone AI Software
PACS/RIS Integrated Plugin
Built-in Solution for Imaging Equipment
Regional Screening Platform System

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the scope of the report and the global market size (value). It also summarizes market dynamics and recent developments; identifies key drivers and restraints; outlines challenges and risks for players; reviews relevant industry policies.

Chapter 2: Provides a detailed analysis of the Lung Cancer Screening Software companies' competitive landscape—including revenue shares, recent development plans, and mergers and acquisitions (M&A).

Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 5: Presents Lung Cancer Screening Software revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.

Chapter 6: Presents Lung Cancer Screening Software revenue at the country level. It provides segmented data by Type and by Application for each country/region.

Chapter 7: Profiles key players, detailing the main companies' product revenue, gross margin, product portfolios, recent developments, etc.

Chapter 8: Analysis of Value Chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Lung Cancer Screening Software Product Introduction

1.2 Global Lung Cancer Screening Software Market Size Forecast (2021–2032)

1.3 Lung Cancer Screening Software Market Trends & Drivers

1.3.1 Lung Cancer Screening Software Industry Trends

1.3.2 Lung Cancer Screening Software Market Drivers & Opportunities

1.3.3 Lung Cancer Screening Software Market Challenges

1.3.4 Lung Cancer Screening Software Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Lung Cancer Screening Software Players Revenue Ranking (2025)

2.2 Global Lung Cancer Screening Software Revenue by Company (2021–2026)

2.3 Key Companies’ R&D and Operations Footprint and Headquarters

2.4 Key Companies Lung Cancer Screening Software Product Offerings

2.5 Key Companies General Availability (GA) Timeline for Lung Cancer Screening Software

2.6 Lung Cancer Screening Software Market Competitive Analysis

2.6.1 Lung Cancer Screening Software Market Concentration Rate (2021–2026)

2.6.2 Top 5 and Top 10 Global Companies by Lung Cancer Screening Software Revenue in 2025

2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Lung Cancer Screening Software revenue, 2025

2.7 Mergers & Acquisitions and Expansion

3 Segmentation Lung Cancer Screening Software Market Classification

3.1 Introduction by Type

3.1.1 Cloud-Based

3.1.2 Web-Based

3.1.3 Global Lung Cancer Screening Software Sales Value by Type

3.1.3.1 Global Lung Cancer Screening Software Sales Value by Type (2021 vs 2025 vs 2032)

3.1.3.2 Global Lung Cancer Screening Software Sales Value, by Type (2021–2032)

3.1.3.3 Global Lung Cancer Screening Software Sales Value, by Type (%), 2021–2032

3.2 Introduction by Screening Technologies

3.2.1 Nodule Detection

3.2.2 Nodule Analysis

3.2.3 Full-Process Screening

3.2.4 Predictive Assessment

3.2.5 Global Lung Cancer Screening Software Sales Value by Screening Technologies

3.2.5.1 Global Lung Cancer Screening Software Sales Value by Screening Technologies (2021 vs 2025 vs 2032)

3.2.5.2 Global Lung Cancer Screening Software Sales Value, by Screening Technologies (2021–2032)

3.2.5.3 Global Lung Cancer Screening Software Sales Value, by Screening Technologies (%), 2021–2032

3.3 Introduction by System Integration Level

3.3.1 Standalone AI Software

3.3.2 PACS/RIS Integrated Plugin

3.3.3 Built-in Solution for Imaging Equipment

3.3.4 Regional Screening Platform System

3.3.5 Global Lung Cancer Screening Software Sales Value by System Integration Level

3.3.5.1 Global Lung Cancer Screening Software Sales Value by System Integration Level (2021 vs 2025 vs 2032)

3.3.5.2 Global Lung Cancer Screening Software Sales Value, by System Integration Level (2021–2032)

3.3.5.3 Global Lung Cancer Screening Software Sales Value, by System Integration Level (%), 2021–2032

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospitals

4.1.2 Medical Examination Institutions

4.1.3 Public Health Screening

4.1.4 Others

4.2 Global Lung Cancer Screening Software Sales Value by Application

4.2.1 Global Lung Cancer Screening Software Sales Value by Application (2021 vs 2025 vs 2032)

4.2.2 Global Lung Cancer Screening Software Sales Value by Application (2021–2032)

4.2.3 Global Lung Cancer Screening Software Sales Value by Application (%), 2021–2032

5 Segmentation by Region

5.1 Global Lung Cancer Screening Software Sales Value by Region

5.1.1 Global Lung Cancer Screening Software Sales Value by Region: 2021 vs 2025 vs 2032

5.1.2 Global Lung Cancer Screening Software Sales Value by Region (2021–2026)

5.1.3 Global Lung Cancer Screening Software Sales Value by Region (2027–2032)

5.1.4 Global Lung Cancer Screening Software Sales Value by Region (%), 2021–2032

5.2 North America

5.2.1 North America Lung Cancer Screening Software Sales Value, 2021–2032

5.2.2 North America Lung Cancer Screening Software Sales Value by Country (%), 2025 vs 2032

5.3 Europe

5.3.1 Europe Lung Cancer Screening Software Sales Value, 2021–2032

5.3.2 Europe Lung Cancer Screening Software Sales Value by Country (%), 2025 vs 2032

5.4 Asia Pacific

5.4.1 Asia Pacific Lung Cancer Screening Software Sales Value, 2021–2032

5.4.2 Asia Pacific Lung Cancer Screening Software Sales Value by Subregion (%), 2025 vs 2032

5.5 South America

5.5.1 South America Lung Cancer Screening Software Sales Value, 2021–2032

5.5.2 South America Lung Cancer Screening Software Sales Value by Country (%), 2025 vs 2032

5.6 Middle East & Africa

5.6.1 Middle East & Africa Lung Cancer Screening Software Sales Value, 2021–2032

5.6.2 Middle East & Africa Lung Cancer Screening Software Sales Value by Country (%), 2025 vs 2032

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Lung Cancer Screening Software Sales Value Growth Trends, 2021 vs 2025 vs 2032

6.2 Key Countries/Regions Lung Cancer Screening Software Sales Value, 2021–2032

6.3 United States

6.3.1 United States Lung Cancer Screening Software Sales Value, 2021–2032

6.3.2 United States Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

6.3.3 United States Lung Cancer Screening Software Sales Value by Application, 2025 vs 2032

6.4 Europe

6.4.1 Europe Lung Cancer Screening Software Sales Value, 2021–2032

6.4.2 Europe Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

6.4.3 Europe Lung Cancer Screening Software Sales Value by Application, 2025 vs 2032

6.5 China

6.5.1 China Lung Cancer Screening Software Sales Value, 2021–2032

6.5.2 China Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

6.5.3 China Lung Cancer Screening Software Sales Value by Application, 2025 vs 2032

6.6 Japan

6.6.1 Japan Lung Cancer Screening Software Sales Value, 2021–2032

6.6.2 Japan Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

6.6.3 Japan Lung Cancer Screening Software Sales Value by Application, 2025 vs 2032

6.7 South Korea

6.7.1 South Korea Lung Cancer Screening Software Sales Value, 2021–2032

6.7.2 South Korea Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

6.7.3 South Korea Lung Cancer Screening Software Sales Value by Application, 2025 vs 2032

6.8 Southeast Asia

6.8.1 Southeast Asia Lung Cancer Screening Software Sales Value, 2021–2032

6.8.2 Southeast Asia Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

6.8.3 Southeast Asia Lung Cancer Screening Software Sales Value by Application, 2025 vs 2032

6.9 India

6.9.1 India Lung Cancer Screening Software Sales Value, 2021–2032

6.9.2 India Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

6.9.3 India Lung Cancer Screening Software Sales Value by Application, 2025 vs 2032

7 Company Profiles

7.1 Siemens Healthineers

7.1.1 Siemens Healthineers Profile

7.1.2 Siemens Healthineers Main Business

7.1.3 Siemens Healthineers Lung Cancer Screening Software Products, Services, and Solutions

7.1.4 Siemens Healthineers Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.1.5 Siemens Healthineers Recent Developments

7.2 GE HealthCare

7.2.1 GE HealthCare Profile

7.2.2 GE HealthCare Main Business

7.2.3 GE HealthCare Lung Cancer Screening Software Products, Services, and Solutions

7.2.4 GE HealthCare Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.2.5 GE HealthCare Recent Developments

7.3 Philips Healthcare

7.3.1 Philips Healthcare Profile

7.3.2 Philips Healthcare Main Business

7.3.3 Philips Healthcare Lung Cancer Screening Software Products, Services, and Solutions

7.3.4 Philips Healthcare Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.3.5 Philips Healthcare Recent Developments

7.4 Canon Medical Systems

7.4.1 Canon Medical Systems Profile

7.4.2 Canon Medical Systems Main Business

7.4.3 Canon Medical Systems Lung Cancer Screening Software Products, Services, and Solutions

7.4.4 Canon Medical Systems Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.4.5 Canon Medical Systems Recent Developments

7.5 United Imaging Healthcare

7.5.1 United Imaging Healthcare Profile

7.5.2 United Imaging Healthcare Main Business

7.5.3 United Imaging Healthcare Lung Cancer Screening Software Products, Services, and Solutions

7.5.4 United Imaging Healthcare Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.5.5 United Imaging Healthcare Recent Developments

7.6 InferVision

7.6.1 InferVision Profile

7.6.2 InferVision Main Business

7.6.3 InferVision Lung Cancer Screening Software Products, Services, and Solutions

7.6.4 InferVision Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.6.5 InferVision Recent Developments

7.7 Airdoc

7.7.1 Airdoc Profile

7.7.2 Airdoc Main Business

7.7.3 Airdoc Lung Cancer Screening Software Products, Services, and Solutions

7.7.4 Airdoc Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.7.5 Airdoc Recent Developments

7.8 VUNO

7.8.1 VUNO Profile

7.8.2 VUNO Main Business

7.8.3 VUNO Lung Cancer Screening Software Products, Services, and Solutions

7.8.4 VUNO Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.8.5 VUNO Recent Developments

7.9 Lunit

7.9.1 Lunit Profile

7.9.2 Lunit Main Business

7.9.3 Lunit Lung Cancer Screening Software Products, Services, and Solutions

7.9.4 Lunit Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.9.5 Lunit Recent Developments

7.10 Qure.ai

7.10.1 Qure.ai Profile

7.10.2 Qure.ai Main Business

7.10.3 Qure.ai Lung Cancer Screening Software Products, Services, and Solutions

7.10.4 Qure.ai Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.10.5 Qure.ai Recent Developments

7.11 Riverain Technologies

7.11.1 Riverain Technologies Profile

7.11.2 Riverain Technologies Main Business

7.11.3 Riverain Technologies Lung Cancer Screening Software Products, Services, and Solutions

7.11.4 Riverain Technologies Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.11.5 Riverain Technologies Recent Developments

7.12 Zebra Medical Vision

7.12.1 Zebra Medical Vision Profile

7.12.2 Zebra Medical Vision Main Business

7.12.3 Zebra Medical Vision Lung Cancer Screening Software Products, Services, and Solutions

7.12.4 Zebra Medical Vision Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.12.5 Zebra Medical Vision Recent Developments

7.13 Arterys

7.13.1 Arterys Profile

7.13.2 Arterys Main Business

7.13.3 Arterys Lung Cancer Screening Software Products, Services, and Solutions

7.13.4 Arterys Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.13.5 Arterys Recent Developments

7.14 Deepwise

7.14.1 Deepwise Profile

7.14.2 Deepwise Main Business

7.14.3 Deepwise Lung Cancer Screening Software Products, Services, and Solutions

7.14.4 Deepwise Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.14.5 Deepwise Recent Developments

7.15 EverFortune AI

7.15.1 EverFortune AI Profile

7.15.2 EverFortune AI Main Business

7.15.3 EverFortune AI Lung Cancer Screening Software Products, Services, and Solutions

7.15.4 EverFortune AI Lung Cancer Screening Software Revenue (US$ Million), 2021–2026

7.15.5 EverFortune AI Recent Developments

8 Industry Chain Analysis

8.1 Lung Cancer Screening Software Value Chain

8.2 Lung Cancer Screening Software Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Key Suppliers of Raw Materials

8.2.3 Cost Structure

8.3 Midstream Analysis

8.4 Downstream (Customer) Analysis

8.5 Sales Model and Sales Channelss

8.5.1 Lung Cancer Screening Software Sales Model

8.5.2 Sales Channels

8.5.3 Lung Cancer Screening Software Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Lung Cancer Screening Software Market Trends

Table 2. Lung Cancer Screening Software Market Drivers & Opportunities

Table 3. Lung Cancer Screening Software Market Challenges

Table 4. Lung Cancer Screening Software Market Restraints

Table 5. Global Lung Cancer Screening Software Revenue by Company (US$ Million), 2021–2026

Table 6. Global Lung Cancer Screening Software Revenue Market Share by Company (2021–2026)

Table 7. Key Companies’ R&D and Operations Footprint and Headquarters

Table 8. Key Companies Lung Cancer Screening Software Product Type

Table 9. Key Companies General Availability (GA) Timeline for Lung Cancer Screening Software

Table 10. Global Lung Cancer Screening Software Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Lung Cancer Screening Software revenue, 2025

Table 12. Mergers & Acquisitions and Expansion Plans

Table 13. Global Lung Cancer Screening Software Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)

Table 14. Global Lung Cancer Screening Software Sales Value by Type (US$ Million), 2021–2026

Table 15. Global Lung Cancer Screening Software Sales Value by Type (US$ Million), 2027–2032

Table 16. Global Lung Cancer Screening Software Sales Market Share in Value by Type (2021–2026)

Table 17. Global Lung Cancer Screening Software Sales Market Share in Value by Type (2027–2032)

Table 18. Global Lung Cancer Screening Software Sales Value by Screening Technologies: 2021 vs 2025 vs 2032 (US$ Million)

Table 19. Global Lung Cancer Screening Software Sales Value by Screening Technologies (US$ Million), 2021–2026

Table 20. Global Lung Cancer Screening Software Sales Value by Screening Technologies (US$ Million), 2027–2032

Table 21. Global Lung Cancer Screening Software Sales Market Share in Value by Screening Technologies (2021–2026)

Table 22. Global Lung Cancer Screening Software Sales Market Share in Value by Screening Technologies (2027–2032)

Table 23. Global Lung Cancer Screening Software Sales Value by System Integration Level: 2021 vs 2025 vs 2032 (US$ Million)

Table 24. Global Lung Cancer Screening Software Sales Value by System Integration Level (US$ Million), 2021–2026

Table 25. Global Lung Cancer Screening Software Sales Value by System Integration Level (US$ Million), 2027–2032

Table 26. Global Lung Cancer Screening Software Sales Market Share in Value by System Integration Level (2021–2026)

Table 27. Global Lung Cancer Screening Software Sales Market Share in Value by System Integration Level (2027–2032)

Table 28. Global Lung Cancer Screening Software Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)

Table 29. Global Lung Cancer Screening Software Sales Value by Application (US$ Million), 2021–2026

Table 30. Global Lung Cancer Screening Software Sales Value by Application (US$ Million), 2027–2032

Table 31. Global Lung Cancer Screening Software Sales Market Share in Value by Application (2021–2026)

Table 32. Global Lung Cancer Screening Software Sales Market Share in Value by Application (2027–2032)

Table 33. Global Lung Cancer Screening Software Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032

Table 34. Global Lung Cancer Screening Software Sales Value by Region (US$ Million), 2021–2026

Table 35. Global Lung Cancer Screening Software Sales Value by Region (US$ Million), 2027–2032

Table 36. Global Lung Cancer Screening Software Sales Value by Region (%), 2021–2026

Table 37. Global Lung Cancer Screening Software Sales Value by Region (%), 2027–2032

Table 38. Key Countries/Regions Lung Cancer Screening Software Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032

Table 39. Key Countries/Regions Lung Cancer Screening Software Sales Value, (US$ Million), 2021–2026

Table 40. Key Countries/Regions Lung Cancer Screening Software Sales Value, (US$ Million), 2027–2032

Table 41. Siemens Healthineers Basic Information List

Table 42. Siemens Healthineers Description and Business Overview

Table 43. Siemens Healthineers Lung Cancer Screening Software Products, Services, and Solutions

Table 44. Revenue (US$ Million) in Lung Cancer Screening Software Business of Siemens Healthineers (2021–2026)

Table 45. Siemens Healthineers Recent Developments

Table 46. GE HealthCare Basic Information List

Table 47. GE HealthCare Description and Business Overview

Table 48. GE HealthCare Lung Cancer Screening Software Products, Services, and Solutions

Table 49. Revenue (US$ Million) in Lung Cancer Screening Software Business of GE HealthCare (2021–2026)

Table 50. GE HealthCare Recent Developments

Table 51. Philips Healthcare Basic Information List

Table 52. Philips Healthcare Description and Business Overview

Table 53. Philips Healthcare Lung Cancer Screening Software Products, Services, and Solutions

Table 54. Revenue (US$ Million) in Lung Cancer Screening Software Business of Philips Healthcare (2021–2026)

Table 55. Philips Healthcare Recent Developments

Table 56. Canon Medical Systems Basic Information List

Table 57. Canon Medical Systems Description and Business Overview

Table 58. Canon Medical Systems Lung Cancer Screening Software Products, Services, and Solutions

Table 59. Revenue (US$ Million) in Lung Cancer Screening Software Business of Canon Medical Systems (2021–2026)

Table 60. Canon Medical Systems Recent Developments

Table 61. United Imaging Healthcare Basic Information List

Table 62. United Imaging Healthcare Description and Business Overview

Table 63. United Imaging Healthcare Lung Cancer Screening Software Products, Services, and Solutions

Table 64. Revenue (US$ Million) in Lung Cancer Screening Software Business of United Imaging Healthcare (2021–2026)

Table 65. United Imaging Healthcare Recent Developments

Table 66. InferVision Basic Information List

Table 67. InferVision Description and Business Overview

Table 68. InferVision Lung Cancer Screening Software Products, Services, and Solutions

Table 69. Revenue (US$ Million) in Lung Cancer Screening Software Business of InferVision (2021–2026)

Table 70. InferVision Recent Developments

Table 71. Airdoc Basic Information List

Table 72. Airdoc Description and Business Overview

Table 73. Airdoc Lung Cancer Screening Software Products, Services, and Solutions

Table 74. Revenue (US$ Million) in Lung Cancer Screening Software Business of Airdoc (2021–2026)

Table 75. Airdoc Recent Developments

Table 76. VUNO Basic Information List

Table 77. VUNO Description and Business Overview

Table 78. VUNO Lung Cancer Screening Software Products, Services, and Solutions

Table 79. Revenue (US$ Million) in Lung Cancer Screening Software Business of VUNO (2021–2026)

Table 80. VUNO Recent Developments

Table 81. Lunit Basic Information List

Table 82. Lunit Description and Business Overview

Table 83. Lunit Lung Cancer Screening Software Products, Services, and Solutions

Table 84. Revenue (US$ Million) in Lung Cancer Screening Software Business of Lunit (2021–2026)

Table 85. Lunit Recent Developments

Table 86. Qure.ai Basic Information List

Table 87. Qure.ai Description and Business Overview

Table 88. Qure.ai Lung Cancer Screening Software Products, Services, and Solutions

Table 89. Revenue (US$ Million) in Lung Cancer Screening Software Business of Qure.ai (2021–2026)

Table 90. Qure.ai Recent Developments

Table 91. Riverain Technologies Basic Information List

Table 92. Riverain Technologies Description and Business Overview

Table 93. Riverain Technologies Lung Cancer Screening Software Products, Services, and Solutions

Table 94. Revenue (US$ Million) in Lung Cancer Screening Software Business of Riverain Technologies (2021–2026)

Table 95. Riverain Technologies Recent Developments

Table 96. Zebra Medical Vision Basic Information List

Table 97. Zebra Medical Vision Description and Business Overview

Table 98. Zebra Medical Vision Lung Cancer Screening Software Products, Services, and Solutions

Table 99. Revenue (US$ Million) in Lung Cancer Screening Software Business of Zebra Medical Vision (2021–2026)

Table 100. Zebra Medical Vision Recent Developments

Table 101. Arterys Basic Information List

Table 102. Arterys Description and Business Overview

Table 103. Arterys Lung Cancer Screening Software Products, Services, and Solutions

Table 104. Revenue (US$ Million) in Lung Cancer Screening Software Business of Arterys (2021–2026)

Table 105. Arterys Recent Developments

Table 106. Deepwise Basic Information List

Table 107. Deepwise Description and Business Overview

Table 108. Deepwise Lung Cancer Screening Software Products, Services, and Solutions

Table 109. Revenue (US$ Million) in Lung Cancer Screening Software Business of Deepwise (2021–2026)

Table 110. Deepwise Recent Developments

Table 111. EverFortune AI Basic Information List

Table 112. EverFortune AI Description and Business Overview

Table 113. EverFortune AI Lung Cancer Screening Software Products, Services, and Solutions

Table 114. Revenue (US$ Million) in Lung Cancer Screening Software Business of EverFortune AI (2021–2026)

Table 115. EverFortune AI Recent Developments

Table 116. Revenue (US$ Million) in Lung Cancer Screening Software Business of Company 40 (2021–2026)

Table 117. Company 40 Recent Developments

Table 118. Key Raw Materials Lists

Table 119. Key Suppliers of Raw Materials Lists

Table 120. Lung Cancer Screening Software Downstream Customers

Table 121. Lung Cancer Screening Software Distributors List

Table 122. Research Programs/Design for This Report

Table 123. Key Data Information from Secondary Sources

Table 124. Key Data Information from Primary Sources

List of Figures

Figure 1. Lung Cancer Screening Software Product Picture

Figure 2. Global Lung Cancer Screening Software Sales Value, 2021 vs 2025 vs 2032 (US$ Million)

Figure 3. Global Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 4. Lung Cancer Screening Software Report Years Considered

Figure 5. Global Lung Cancer Screening Software Players Revenue Ranking (US$ Million), 2025

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Lung Cancer Screening Software Revenue in 2025

Figure 7. Lung Cancer Screening Software Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 8. Cloud-Based Picture

Figure 9. Web-Based Picture

Figure 10. Global Lung Cancer Screening Software Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032

Figure 11. Global Lung Cancer Screening Software Sales Value Market Share by Type, 2025 & 2032

Figure 12. Nodule Detection Picture

Figure 13. Nodule Analysis Picture

Figure 14. Full-Process Screening Picture

Figure 15. Predictive Assessment Picture

Figure 16. Global Lung Cancer Screening Software Sales Value by Screening Technologies (US$ Million), 2021 vs 2025 vs 2032

Figure 17. Global Lung Cancer Screening Software Sales Value Market Share by Screening Technologies, 2025 & 2032

Figure 18. Standalone AI Software Picture

Figure 19. PACS/RIS Integrated Plugin Picture

Figure 20. Built-in Solution for Imaging Equipment Picture

Figure 21. Regional Screening Platform System Picture

Figure 22. Global Lung Cancer Screening Software Sales Value by System Integration Level (US$ Million), 2021 vs 2025 vs 2032

Figure 23. Global Lung Cancer Screening Software Sales Value Market Share by System Integration Level, 2025 & 2032

Figure 24. Product Picture of Hospitals

Figure 25. Product Picture of Medical Examination Institutions

Figure 26. Product Picture of Public Health Screening

Figure 27. Product Picture of Others

Figure 28. Global Lung Cancer Screening Software Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032

Figure 29. Global Lung Cancer Screening Software Sales Value Market Share by Application, 2025 & 2032

Figure 30. North America Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 31. North America Lung Cancer Screening Software Sales Value by Country (%), 2025 vs 2032

Figure 32. Europe Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 33. Europe Lung Cancer Screening Software Sales Value by Country (%), 2025 vs 2032

Figure 34. Asia Pacific Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 35. Asia Pacific Lung Cancer Screening Software Sales Value by Subregion (%), 2025 vs 2032

Figure 36. South America Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 37. South America Lung Cancer Screening Software Sales Value by Country (%), 2025 vs 2032

Figure 38. Middle East & Africa Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 39. Middle East & Africa Lung Cancer Screening Software Sales Value by Country (%), 2025 vs 2032

Figure 40. Key Countries/Regions Lung Cancer Screening Software Sales Value (%), 2021–2032

Figure 41. United States Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 42. United States Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

Figure 43. United States Lung Cancer Screening Software Sales Value by Application (%), 2025 vs 2032

Figure 44. Europe Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 45. Europe Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

Figure 46. Europe Lung Cancer Screening Software Sales Value by Application (%), 2025 vs 2032

Figure 47. China Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 48. China Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

Figure 49. China Lung Cancer Screening Software Sales Value by Application (%), 2025 vs 2032

Figure 50. Japan Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 51. Japan Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

Figure 52. Japan Lung Cancer Screening Software Sales Value by Application (%), 2025 vs 2032

Figure 53. South Korea Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 54. South Korea Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

Figure 55. South Korea Lung Cancer Screening Software Sales Value by Application (%), 2025 vs 2032

Figure 56. Southeast Asia Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 57. Southeast Asia Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

Figure 58. Southeast Asia Lung Cancer Screening Software Sales Value by Application (%), 2025 vs 2032

Figure 59. India Lung Cancer Screening Software Sales Value (US$ Million), 2021–2032

Figure 60. India Lung Cancer Screening Software Sales Value by Type (%), 2025 vs 2032

Figure 61. India Lung Cancer Screening Software Sales Value by Application (%), 2025 vs 2032

Figure 62. Lung Cancer Screening Software Value Chain

Figure 63. Lung Cancer Screening Software Cost Structure

Figure 64. Channels of Distribution (Direct Sales, and Distribution)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Lung Cancer Screening Software in 2032? zhanKai

The global market size of Lung Cancer Screening Software in 2032 was 5434 Million USD.

What is the annual compound growth rate of the global Lung Cancer Screening Software market size from 2026 to 2032? shouQi

Which region is expected to have the highest market share? shouQi

What was the global market size of Lung Cancer Screening Software in 2026? shouQi

Which companies rank high in the global Lung Cancer Screening Software market? shouQi

Related Reports

Global Lung Cancer Screening Software Market Research Report 2026
The global Lung Cancer Screening Software market was valued at US$ 1706 million in 2025 and is anticipated to reach US$ 5434 million by 2032, at a CAGR of 18.0% from 2026 to 2032.
Published Date: 2026-01-14
Pages: 115
USD 2900.00
(Single User License)
Global Lung Cancer Screening Software Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Lung Cancer Screening Software market is projected to grow from US$ 1706 million in 2025 to US$ 5434 million by 2032, at a CAGR of 18.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-01-14
Pages: 132
USD 4900.00
(Single User License)
Global Lung Cancer Screening Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Lung Cancer Screening Software market size was US$ 1706 million in 2025 and is forecast to reach a readjusted size of US$ 5434 million by 2032 with a CAGR of 18.0% during the forecast period 2026-2032.
Published Date: 2026-01-14
Pages: 98
USD 4250.00
(Single User License)
Global Lung Cancer Screening Software Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Lung Cancer Screening Software market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-10-23
Pages: 126
USD 4900.00
(Single User License)
Global Lung Cancer Screening Software Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Lung Cancer Screening Software market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-20
Pages: 77
USD 4250.00
(Single User License)
Lung Cancer Screening Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Lung Cancer Screening Software was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-20
Pages: 100
USD 3950.00
(Single User License)
Global Lung Cancer Screening Software Market Research Report 2025
The global market for Lung Cancer Screening Software was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-20
Pages: 74
USD 2900.00
(Single User License)
Global Lung Cancer Screening Software Market Insights, Forecast to 2030
Market Analysis and Insights: Global Lung Cancer Screening Software Market
Published Date: 2024-04-07
Pages: 89
USD 4900.00
(Single User License)
Lung Cancer Screening Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Lung Cancer Screening Software was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Published Date: 2024-02-19
Pages: 92
USD 3950.00
(Single User License)
Global Lung Cancer Screening Software Market Research Report 2024
The global Lung Cancer Screening Software market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published Date: 2024-01-11
Pages: 79
USD 2900.00
(Single User License)

Global Lung Cancer Screening Software Market Research Report 2026
The global Lung Cancer Screening Software market was valued at US$ 1706 million in 2025 and is anticipated to reach US$ 5434 million by 2032, at a CAGR of 18.0% from 2026 to 2032.
Published: 2026-01-14
Pages: 115
USD 2900.00 (Single User License)
Global Lung Cancer Screening Software Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Lung Cancer Screening Software market is projected to grow from US$ 1706 million in 2025 to US$ 5434 million by 2032, at a CAGR of 18.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-01-14
Pages: 132
USD 4900.00 (Single User License)
Global Lung Cancer Screening Software Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Lung Cancer Screening Software market size was US$ 1706 million in 2025 and is forecast to reach a readjusted size of US$ 5434 million by 2032 with a CAGR of 18.0% during the forecast period 2026-2032.
Published: 2026-01-14
Pages: 98
USD 4250.00 (Single User License)
Global Lung Cancer Screening Software Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Lung Cancer Screening Software market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-10-23
Pages: 126
USD 4900.00 (Single User License)
Global Lung Cancer Screening Software Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Lung Cancer Screening Software market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-20
Pages: 77
USD 4250.00 (Single User License)
Lung Cancer Screening Software- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Lung Cancer Screening Software was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-20
Pages: 100
USD 3950.00 (Single User License)
Global Lung Cancer Screening Software Market Research Report 2025
The global market for Lung Cancer Screening Software was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-20
Pages: 74
USD 2900.00 (Single User License)
Global Lung Cancer Screening Software Market Insights, Forecast to 2030
Market Analysis and Insights: Global Lung Cancer Screening Software Market
Published: 2024-04-07
Pages: 89
USD 4900.00 (Single User License)
Lung Cancer Screening Software - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Lung Cancer Screening Software was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
Published: 2024-02-19
Pages: 92
USD 3950.00 (Single User License)
Global Lung Cancer Screening Software Market Research Report 2024
The global Lung Cancer Screening Software market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Published: 2024-01-11
Pages: 79
USD 2900.00 (Single User License)